deoxycholic-acid and Pharyngeal-Neoplasms

In this study, we reported a redox-responsive drug delivery system (DDS) based on heparosan and deoxycholic acid conjugates (HSDs) for effective treatment of laryngopharyngeal carcinoma. The amphiphilic HSDs can self-assemble into stable nanoscale micelles in aqueous medium with favorable drug loading capacity for doxorubicin (DOX). The HSD micelles can exhibit glutathione (GSH)-triggered drug release behavior and reach a nearly 100% release rate in a high GSH level (10 mM) environment. Moreover, FaDu cancer cells can internalize HSD micelles by clathrin-mediated endocytosis, which is energy dependent, fast, and effective. The DOX@HSD induced inhibition of FaDu cancer cells can achieve a minimum of 10-fold selectivity relative to that of COS-7 normal cells. Overall, the redox-responsive DDSs show good biocompatibility and are promising in the clinical treatment of laryngopharyngeal carcinoma.

Topics: Animals; Chlorocebus aethiops; Clathrin; COS Cells; Deoxycholic Acid; Disaccharides; Doxorubicin; Drug Delivery Systems; Drug Liberation; Endocytosis; HeLa Cells; Humans; Laryngeal Neoplasms; Nanoparticles; Oxidation-Reduction; Pharyngeal Neoplasms; Polyethylene Glycols; Polymers